

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING**Product Identifier****Material Name: Medroxyprogesterone Acetate Tablets (Greenstone LLC)****Trade Name:** Not applicable
Chemical Family: Synthetic progestogen**Relevant Identified Uses of the Substance or Mixture and Uses Advised Against****Intended Use:** Pharmaceutical product**Details of the Supplier of the Safety Data Sheet**Greenstone LLC
100 Route 206 North
Peapack, NJ 07977
800-435-7095**Emergency telephone number:**
CHEMTREC (24 hours): 1-800-424-9300**2. HAZARDS IDENTIFICATION****Classification of the Substance or Mixture****GHS - Classification**Reproductive Toxicity: Category 1A
Carcinogenicity: Category 2**EU Classification:**EU Indication of danger: Toxic to reproduction: Category 1
Carcinogenic: Category 3**EU Risk Phrases:**R60 - May impair fertility.
R40 - Limited evidence of a carcinogenic effect.
R61 - May cause harm to the unborn child.**Label Elements****Signal Word:** Danger
Hazard Statements: H351 - Suspected of causing cancer
H360FD - May damage fertility. May damage the unborn child.**Precautionary Statements:** P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 2 of 11

Version: 5.0

Other Hazards No data available
Australian Hazard Classification (NOHSC): Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

| Ingredient | CAS Number | EU EINECS/ELINCS List | EU Classification | GHS Classification | % |
|-----------------------------|------------|-----------------------|---------------------------------------|-------------------------------------|---------------------|
| Maize starch | 9005-25-8 | 232-679-6 | Not Listed | Not Listed | * |
| Medroxyprogesterone acetate | 71-58-9 | 200-757-9 | Carc. Cat.3;R40 Repr. Cat.1;R60-61 | Carc. 2 (H351) Repr. 1A (H360FD) | 2.5, 5, or 10 mg*** |
| Sucrose | 57-50-1 | 200-334-9 | Not Listed | Not Listed | * |
| Talc (non-asbestiform) | 14807-96-6 | 238-877-9 | Not Listed | Not Listed | * |
| Calcium stearate | 1592-23-0 | 216-472-8 | Not Listed | Not Listed | * |
| Mineral oil | 8012-95-1 | 232-384-2 | Not Listed | Not Listed | * |

| Ingredient | CAS Number | EU EINECS/ELINCS List | EU Classification | GHS Classification | % |
|-------------------------|------------|-----------------------|-------------------|--------------------|---|
| Lactose NF, monohydrate | 64044-51-5 | Not Listed | Not Listed | Not Listed | * |
| Sorbic acid | 110-44-1 | 203-768-7 | Not Listed | Not Listed | * |

Additional Information: * Proprietary
*** per tablet/capsule/lozenge/suppository
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 3 of 11

Version: 5.0

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 4 of 11

Version: 5.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Maize starch

| | |
|-----------------------------------|------------------------|
| ACGIH Threshold Limit Value (TWA) | 10 mg/m ³ |
| Australia TWA | 10 mg/m ³ |
| Belgium OEL - TWA | 10 mg/m ³ |
| Bulgaria OEL - TWA | 10.0 mg/m ³ |
| Czech Republic OEL - TWA | 4.0 mg/m ³ |
| Greece OEL - TWA | 10 mg/m ³ |
| | 5 mg/m ³ |
| Ireland OEL - TWAs | 10 mg/m ³ |
| | 4 mg/m ³ |
| OSHA - Final PELs - TWAs: | 15 mg/m ³ |
| Portugal OEL - TWA | 10 mg/m ³ |
| Slovakia OEL - TWA | 4 mg/m ³ |
| Spain OEL - TWA | 10 mg/m ³ |

Medroxyprogesterone acetate

Manufacturer OEL: 2ug/m³, Skin

Sucrose

| | |
|-----------------------------------|------------------------|
| ACGIH Threshold Limit Value (TWA) | 10 mg/m ³ |
| Australia TWA | 10 mg/m ³ |
| Belgium OEL - TWA | 10 mg/m ³ |
| Bulgaria OEL - TWA | 10.0 mg/m ³ |
| Estonia OEL - TWA | 10 mg/m ³ |
| France OEL - TWA | 10 mg/m ³ |
| Ireland OEL - TWAs | 10 mg/m ³ |
| Latvia OEL - TWA | 5 mg/m ³ |
| Lithuania OEL - TWA | 10 mg/m ³ |
| OSHA - Final PELs - TWAs: | 15 mg/m ³ |
| Portugal OEL - TWA | 10 mg/m ³ |
| Slovakia OEL - TWA | 6 mg/m ³ |
| Spain OEL - TWA | 10 mg/m ³ |

Talc (non-asbestiform)

| | |
|-----------------------------------|---------------------------|
| ACGIH Threshold Limit Value (TWA) | 2 mg/m ³ |
| Australia TWA | 2.5 mg/m ³ |
| Austria OEL - MAKs | 2 mg/m ³ |
| Belgium OEL - TWA | 2 mg/m ³ |
| Bulgaria OEL - TWA | 1.0 fiber/cm ³ |
| | 6.0 mg/m ³ |
| | 3.0 mg/m ³ |
| Czech Republic OEL - TWA | 2.0 mg/m ³ |
| Denmark OEL - TWA | 0.3 fiber/cm ³ |
| Finland OEL - TWA | 0.5 fiber/cm ³ |
| Greece OEL - TWA | 10 mg/m ³ |
| | 2 mg/m ³ |
| Hungary OEL - TWA | 2 mg/m ³ |

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 5 of 11

Version: 5.0

| | |
|--|------------------------|
| Ireland OEL - TWAs | 10 mg/m ³ |
| | 0.8 mg/m ³ |
| Lithuania OEL - TWA | 2 mg/m ³ |
| | 1 mg/m ³ |
| Netherlands OEL - TWA | 0.25 mg/m ³ |
| OSHA - Final PELs - Table Z-3 Mineral D: | 20 mppcf |
| Poland OEL - TWA | 4.0 mg/m ³ |
| | 1.0 mg/m ³ |
| Portugal OEL - TWA | 2 mg/m ³ |
| Romania OEL - TWA | 2 mg/m ³ |
| Slovakia OEL - TWA | 2 mg/m ³ |
| | 10 mg/m ³ |
| Slovenia OEL - TWA | 2 mg/m ³ |
| Spain OEL - TWA | 2 mg/m ³ |
| Sweden OEL - TWAs | 2 mg/m ³ |
| | 1 mg/m ³ |

Calcium stearate

| | |
|-----------------------------------|----------------------|
| ACGIH Threshold Limit Value (TWA) | 10 mg/m ³ |
| Lithuania OEL - TWA | 5 mg/m ³ |
| Sweden OEL - TWAs | 5 mg/m ³ |

Mineral oil

| | |
|-----------------------------------|-----------------------|
| ACGIH Threshold Limit Value (TWA) | 5 mg/m ³ |
| Australia TWA | 5 mg/m ³ |
| Belgium OEL - TWA | 5 mg/m ³ |
| Bulgaria OEL - TWA | 5.0 mg/m ³ |
| Czech Republic OEL - TWA | 5 mg/m ³ |
| Denmark OEL - TWA | 1 mg/m ³ |
| Finland OEL - TWA | 5 mg/m ³ |
| Greece OEL - TWA | 5 mg/m ³ |
| Lithuania OEL - TWA | 1 mg/m ³ |
| Netherlands OEL - TWA | 5 mg/m ³ |
| OSHA - Final PELs - TWAs: | 5 mg/m ³ |
| Poland OEL - TWA | 5 mg/m ³ |
| Portugal OEL - TWA | 5 mg/m ³ |
| Romania OEL - TWA | 5 mg/m ³ |
| Slovakia OEL - TWA | 5 ppm |
| | 1 mg/m ³ |
| | 5 mg/m ³ |
| Spain OEL - TWA | 5 mg/m ³ |
| Sweden OEL - TWAs | 1 mg/m ³ |

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 6 of 11

Version: 5.0

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

| | | | |
|---|--------------------|--------------------------|--------------------|
| Physical State: | Tablets | Color: | No data available. |
| Odor: | No data available. | Odor Threshold: | No data available. |
| Molecular Formula: | Mixture | Molecular Weight: | Mixture |
| Solvent Solubility: | No data available | | |
| Water Solubility: | No data available | | |
| pH: | No data available. | | |
| Melting/Freezing Point (°C): | No data available | | |
| Boiling Point (°C): | No data available. | | |
| Partition Coefficient: (Method, pH, Endpoint, Value) | | | |
| Lactose NF, monohydrate | | | |
| No data available | | | |
| Sorbic acid | | | |
| No data available | | | |
| Mineral oil | | | |
| No data available | | | |
| Calcium stearate | | | |
| No data available | | | |
| Maize starch | | | |
| No data available | | | |
| Sucrose | | | |
| No data available | | | |
| Talc (non-asbestiform) | | | |
| No data available | | | |
| Medroxyprogesterone acetate | | | |
| No data available | | | |
| Decomposition Temperature (°C): | No data available. | | |
| Evaporation Rate (Gram/s): | No data available | | |
| Vapor Pressure (kPa): | No data available | | |
| Vapor Density (g/ml): | No data available | | |
| Relative Density: | No data available | | |
| Viscosity: | No data available | | |

Flammability:

| | |
|---|-------------------|
| Autoignition Temperature (Solid) (°C): | No data available |
| Flammability (Solids): | No data available |
| Flash Point (Liquid) (°C): | No data available |
| Upper Explosive Limits (Liquid) (% by Vol.): | No data available |
| Lower Explosive Limits (Liquid) (% by Vol.): | No data available |

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 7 of 11

Version: 5.0

10. STABILITY AND REACTIVITY

| | |
|--|--|
| Oxidizing Properties: | No data available |
| Conditions to Avoid: | Fine particles (such as dust and mists) may fuel fires/explosions. |
| Incompatible Materials: | As a precautionary measure, keep away from strong oxidizers |
| Hazardous Decomposition Products: | No data available |

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:

The information included in this section describes the potential hazards of the individual ingredients.

Long Term:

Repeat-dose studies in animals have shown a potential to cause adverse effects on blood and blood forming organs reproductive system developing fetus Occupational studies have shown that males working with estrogen-like compounds have shown clinical signs of hyperestrogenism including enlarged breasts and milk secretion. Loss of libido, breast tenderness, and changes in sex hormone levels have also occurred. Occupational exposure in females has resulted in menstrual irregularities (breakthrough bleeding, menstrual flow changes, spotting and amenorrhea).

Known Clinical Effects:

Adverse effects associated with therapeutic use of medroxyprogesterone acetate include menstrual irregularities, abdominal pain or discomfort weight changes, dizziness, headache, weakness or fatigue, and nervousness. Clinical use of this drug has caused loss of libido, impotence, and development of male characteristics in the female fetus.

Acute Toxicity: (Species, Route, End Point, Dose)

Sorbic acid

Rat Oral LD50 7360 mg/kg
Mouse Oral LD50 3200mg/kg

Sucrose

Rat Oral LD50 29.7 g/kg

Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

Medroxyprogesterone acetate

Rat Oral LD50 > 6,400 mg/kg
Mouse Para-periosteal LD50 376mg/kg
Rat Intraperitoneal LD50 > 400mg/kg
Rat Subcutaneous LD50 > 8000mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Mineral oil

Eye Irritation Rabbit Moderate
Skin Irritation Rabbit Mild

Medroxyprogesterone acetate

Eye Irritation Rabbit Non-irritating
Skin Irritation Rabbit Mild

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 8 of 11

Version: 5.0

11. TOXICOLOGICAL INFORMATION

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Medroxyprogesterone acetate

| | | | | | |
|-------------|--------|---------------|-----------|-------|---------------------|
| 10 Year(s) | Monkey | Intramuscular | 3 mg/kg | LOAEL | Reproductive system |
| 18 Month(s) | Mouse | Intramuscular | 200 mg/kg | NOAEL | None identified |
| 24 Month(s) | Rat | Intramuscular | 200 mg/kg | NOAEL | None identified |

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Medroxyprogesterone acetate

| | | | | | |
|----------------------------|--------|---------------|----------|-------|---------------------------------|
| Embryo / Fetal Development | Rat | Intramuscular | 3 mg/kg | LOAEL | Embryotoxicity, Not teratogenic |
| Embryo / Fetal Development | Monkey | Intramuscular | 25 mg/kg | LOAEL | Developmental toxicity |
| Embryo / Fetal Development | Rabbit | Intramuscular | 1 mg/kg | LOAEL | Developmental toxicity |
| Embryo / Fetal Development | Rat | Subcutaneous | 1 mg/kg | LOAEL | Developmental toxicity |

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

| | | |
|-------------------------------|-------------------|----------|
| Bacterial Mutagenicity (Ames) | <i>Salmonella</i> | Negative |
|-------------------------------|-------------------|----------|

Medroxyprogesterone acetate

| | | |
|-------------------------------|--------------------|----------|
| Bacterial Mutagenicity (Ames) | <i>Salmonella</i> | Negative |
| Micronucleus | Mouse | Negative |
| Chromosome Aberration | Rodent germ cell | Positive |
| Sister Chromatid Exchange | Rodent Lymphocytes | Positive |

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Medroxyprogesterone acetate

| | | | | |
|-------------|-------|---------------|-----------------|-----------------------------|
| 18 Month(s) | Mouse | Intramuscular | 200 mg/kg/month | Not carcinogenic |
| 24 Month(s) | Rat | Intramuscular | 200 mg/kg/month | Not carcinogenic |
| 18 Month(s) | Dog | Intramuscular | 0.2 mg/kg | LOEL Benign tumors |
| 40 Month(s) | Dog | Intramuscular | 0.3 mg/kg | NOAEL Tumors, Mammary gland |

Carcinogen Status: See below

Talc (non-asbestiform)

IARC: Group 3 (Not Classifiable)

Medroxyprogesterone acetate

IARC: Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

SAFETY DATA SHEET

**Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015**

Page 9 of 11

Version: 5.0

Persistence and Degradability: No data available
Bio-accumulative Potential: No data available
Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Lactose NF, monohydrate

| | |
|--|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Australia (AICS): | Present |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present |
| EU EINECS/ELINCS List | Not Listed |

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 10 of 11

Version: 5.0

15. REGULATORY INFORMATION

Maize starch

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present |
| EU EINECS/ELINCS List | 232-679-6 |

Medroxyprogesterone acetate

| | |
|---|--|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | carcinogen initial date 1/1/90 developmental toxicity initial date 4/1/90 |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 200-757-9 |

Sucrose

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| REACH - Annex IV - Exemptions from the obligations of Register: | Present |
| EU EINECS/ELINCS List | 200-334-9 |

Talc (non-asbestiform)

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 238-877-9 |

Calcium stearate

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 216-472-8 |

Mineral oil

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 232-384-2 |

Sorbic acid

| | |
|---|------------|
| CERCLA/SARA 313 Emission reporting | Not Listed |
| California Proposition 65 | Not Listed |
| Inventory - United States TSCA - Sect. 8(b) | Present |

SAFETY DATA SHEET

Material Name: Medroxyprogesterone Acetate Tablets
(Greenstone LLC)
Revision date: 16-May-2015

Page 11 of 11

Version: 5.0

15. REGULATORY INFORMATION

| | |
|-----------------------|-----------|
| Australia (AICS): | Present |
| EU EINECS/ELINCS List | 203-768-7 |

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Carcinogenicity-Cat.2; H351 - Suspected of causing cancer
Reproductive toxicity-Cat.1A; H360FD - May damage fertility. May damage the unborn child.

Carcinogenic: Category 3
Toxic to reproduction: Category 1

R60 - May impair fertility.
R61 - May cause harm to the unborn child.
R40 - Limited evidence of a carcinogenic effect

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 16 - Other Information.

Revision date: 16-May-2015
Product Stewardship Hazard Communication

Prepared by: Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

End of Safety Data Sheet